Mode
Text Size
Log in / Sign up
Phase 2 N=30 Prevention

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcome: Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
BCG TICE Vaccine (Biological)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
BCG Uptake
48.06; 0.84; 35.97

Summary

This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.

Eligibility Criteria

Inclusion Criteria (CF and non-CF bronchiectasis):

  • Confirmed diagnosis of either CF or non-CF bronchiectasis
  • Forced expiratory volume over one second (FEV1) > 40%
  • Willingness to participate in the study after all aspects of the protocol have been explained and written informed consent obtained.
  • Available for the study duration, including all planned follow-up visits

Inclusion Criteria (Healthy Volunteers):

  • Negative HIV enzyme-linked immunosorbent assay (ELISA) and confirmatory test at screening.
  • Willingness to participate in the study after all aspects of the protocol have been explained and written informed obtained.
  • Available for the study duration, including all planned follow-up visits

Exclusion Criteria (All arms):

  • Current or prior history of active or latent tuberculosis (TB) (per report, not formally tested) or NTM infection
  • Prior BCG vaccination
  • Previous vaccine in the past 4 weeks
  • History of severe anaphylaxis to any vaccine or vaccine components
  • History of organ/bone marrow transplantation or other immunosuppressing condition, including HIV
  • Immunosuppressing drugs (including oral corticosteroids equivalent to >10mg of prednisone for 5 days) in the 30 days prior to study enrollment
  • Cirrhosis or portal hypertension
  • Pregnant or breastfeeding
  • Receipt of another investigational product in the last 28 days or planned receipt during this study
  • Has any other condition that, in the opinion of the principal investigator, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04884308). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search